[1] Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 Years[J]. N Engl J Med,2017,377(1):13-27.
[2] Lim S. A new international journal targeting the pathophysiology and treatment of obesity and metabolic syndrome[J]. J Obes Metab Syndr,2017,26(2):81-83.
[3] Yaribeygi H, Farrokhi FR, Butler AE, et al. Insulin resistance:Review of the underlying molecular mechanisms[J]. J Cell Physiol,2018,234(6):8152-8161.
[4] Smitka K, Marešová D. Adipose tissue as an endocrine organ:An update on pro-inflammatory and anti-inflammatory microenvironment[J]. Prague Med Rep,2015,116(2):87-111.
[5] Odegaard AO, Jacobs DJ, Sanchez OA, et al. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes[J]. Cardiovasc Diabetol,2016,15:51.
[6] Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance[J]. Biomed J,2017,40(5):257-262.
[7] Rehman K, Akash MSH. Mechanisms of inflammatory responses and development of insulin resistance:how are they interlinked?[J]. J Biomed Sci,2016,23(1):87.
[8] Yadav UCS.Oxidative stress-Induced lipid peroxidation:Role in inflammation[M]//Rani V, Yadav UCS.Free radicals in human health and disease.New Delhi:Springer India, 2015:119-129.
[9] Hesselink MKC, Schrauwen-Hinderling V, Schrauwen P. Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus[J]. Nat Rev Endocrinol,2016,12(11):633-645.
[10] Hammarstedt A, Gogg S, Hedjazifar S, et al. Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity[J]. Physiol Rev,2018,98(4):1911-1941.
[11] Poblete JMS, Ballinger MN,Bao S, et al. Macrophage HIF-1α mediates obesity-related adipose tissue dysfunction via interleukin-1 receptor-associated kinase M[J]. Am J Physiol Endocrinol Metab,2020,318(5):E689-E700.
[12] Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease[J]. J Hepatol,2015,62(3):720-733.
[13] Woo CY, Jang JE, Lee SE, et al. Mitochondrial dysfunction in adipocytes as a primary cause of adipose tissue inflammation[J]. Diabetes Metab J,2019,43(3):247-256.
[14] Grand A,Rochette E, Dutheil F, et al. Body mass index and calprotectin blood level correlation in healthy children:An individual patient data meta-analysis[J]. J Clin Med,2020,9(3):857.
[15] Lylloff L, Bathum L, Madsbad S, et al. S100A8/A9 (Calprotectin), interleukin-6, and C-reactive protein in obesity and diabetes before and after Roux-en-Y gastric bypass surgery[J]. Obes Facts,2017,10(4):386-395.
[16] Sekimoto R,Kishida K, Nakatsuji H, et al. High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice[J]. Biochem Biophys Res Commun,2012,419(4):782-789.
[17] Park SY, Kim WJ. A study of fecal calprotectin in obese children and adults[J]. J Obes Metab Syndr,2018,27(4):233-237.
[18] Calcaterra V, De Amici M, Leonard MM, et al. Serum calprotectin level in children:Marker of obesity and its metabolic complications[J]. Ann Nutr Metab,2018,73(3):177-183.
[19] Yao L, Bhatta A, Xu Z, et al. Obesity-induced vascular inflammation involves elevated arginase activity[J]. Am J Physiol Regul Integr Comp Physiol,2017,313(5):R560-R571.
[20] Ding S, Chi MM, Scull BP, et al. High-fat diet:bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse[J].PLoS One,2010,5(8):e12191.
[21] Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota[J]. Lancet Diabetes Endocrinol,2015,3(3):207-215.
[22] Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin:A link between lifestyle factors and colorectal cancer risk[J]. Cancer Epidemiol Biomarkers Prev,2004,13(2):279-284.
[23] Gobel RJ, Jensen SM, Frokiaer H, et al. Obesity, inflammation and metabolic syndrome in Danish adolescents[J]. Acta Paediatr,2012,101(2):192-200.
[24] Ortega FJ,Mercader JM, Moreno-Navarrete JM, et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization[J]. Diabetes Care,2014,37(5):1375-1383.
[25] Shi C, Zhu L, Chen X, et al. IL-6 and TNF-α Induced obesity-related inflammatory response through transcriptional regulation of miR-146b[J]. J Interferon Cytokine Res,2014,34(5):342-348.
[26] Cirillo F, Catellani C, Sartori C, et al. Obesity, Insulin resistance, and colorectal cancer:could miRNA dysregulation play a role?[J]. Int J Mol Sci,2019,20(12):2922.
[27] Wang D, He S, Liu B, et al. MiR-27-3p regulates TLR2/4-dependent mouse alveolar macrophage activation bytargetting PPARγ[J].Clin Sci(Lond),2018,132(9):943-958.
[28] Oses M, Sanchez JM, Portillo MP, et al. Circulating miRNAs as biomarkers of obesity and obesity-associated comorbidities in children and adolescents:a systematic review[J]. Nutrients,2019,11(12):2890.
[29] Herder C,Ouwens DM, Carstensen M, et al. Adiponectin may mediate the association between omentin, circulating lipids and insulin sensitivity:results from the KORA F4 study[J]. Eur J Endocrinol,2015,172(4):423-432.
[30] Buyukinan M, Atar M, Can U, et al. The association between serum vaspin and omentin-1 levels in obese children with metabolic syndrome[J]. Metab Syndr Relat Disord,2018,16(2):76-81.
[31] Zengi S, Zengi O, Kirankaya A, et al. Serum omentin-1 levels in obese children[J]. J Pediatr Endocrinol Metab,2019,32(3):247-251.
[32] Rothermel J, Lass N, Barth A, et al. Link between omentin-1, obesity and insulin resistance in children:Findings from a longitudinal intervention study[J]. Pediatr Obes,2020,15(5):e12605.
[33] Yin C, Hu W, Wang M, et al. The role of theadipocytokines vaspin and visfatin in vascular endothelial function and insulin resistance in obese children[J]. BMC Endocr Disord,2019,19(1):127.
[34] Chang HM, Lee HJ, Park HS, et al. Effects of weight reduction on serum vaspin concentrations in obese subjects:modification by insulin resistance[J].Obesity(Silver Spring),2010,18(11):2105-2110.
[35] Rausch LK, Hofer M,Pramsohler S, et al. Adiponectin, leptin and visfatin in hypoxia and its effect for weight Loss in obesity[J]. Front Endocrinol (Lausanne),2018,9:615.
[36] Garcia-Hermoso A, Ceballos-Ceballos RJM, Poblete-Aro CE, et al. Exercise, adipokines and pediatric obesity:a meta-analysis of randomized controlled trials[J]. Int J Obes (Lond),2017,41(4):475-482.
[37] Reinehr T, Roth CL. Inflammation markers in Type 2 diabetes and the metabolic syndrome in the pediatric population[J]. Curr Diab Rep,2018,18(12):131.
[38] Aggeloussi S, Theodorou AA, Paschalis V, et al. Adipocytokine levels in children:effects of fatness and training[J]. Pediatr Exerc Sci,2012,24(3):461-471.
[39] Novak S,Divkovic D, Drenjancevic I, et al. Visfatin serum level and expression in subcutaneous and visceral adipose tissue in prepubertal boys[J]. Pediatr Obes,2016,11(5):411-417.
[40] Ooi SQ, Chan RME, Poh LKS, et al. Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children[J]. Pediatr Obes,2014,9(2):81-91.